Li Claire Y, Kennedy Timothy, Alexander Henry Richard
Department of Surgery, New York-Presbyterian Hospital and Weill Cornell Medicine, New York, NY 10065, USA.
Division of Surgical Oncology, Department of Surgery, The Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA.
J Clin Med. 2022 Mar 29;11(7):1891. doi: 10.3390/jcm11071891.
Malignant peritoneal mesothelioma is a rare malignancy arising from the serosa of the peritoneal cavity. It is diagnosed based on suspicious findings on cross sectional imaging and a tissue biopsy showing confirmatory histologic and immunohistochemical features. The disease is hallmarked by its propensity to progress mainly in the peritoneal cavity. In selected patients, surgical cytoreduction and hyperthermic intra-operative peritoneal chemotherapy has become the initial preferred treatment and is associated with provide prolonged in many patients. Systemic chemotherapy using a couplet of cisplatin or gemcitabine with pemetrexed has modest response rates and duration of response. Expression of PD-L1 has been demonstrated in peritoneal mesothelioma tumors and there has been significant interest in the use of check point blockade targeted against PD-L1 in this clinical setting. Future clinical research using a combination of check point blockade with surgical cytoreduction is a high clinical priority.
恶性腹膜间皮瘤是一种起源于腹膜腔浆膜的罕见恶性肿瘤。它是根据横断面成像上的可疑发现以及显示确诊的组织学和免疫组化特征的组织活检来诊断的。该疾病的特点是主要倾向于在腹膜腔内进展。在部分患者中，手术减瘤和术中热灌注化疗已成为初始首选治疗方法，并且在许多患者中可延长生存期。使用顺铂或吉西他滨与培美曲塞联合的全身化疗反应率和反应持续时间适中。PD-L1已在腹膜间皮瘤肿瘤中被证实有表达，并且在这种临床情况下使用针对PD-L1的检查点阻断疗法引起了极大关注。未来将检查点阻断与手术减瘤相结合的临床研究是一项高度优先的临床任务。
